Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manesh R Patel

Showing results (501-510 of 596) with videos related to

Pageof 60
Sort By:
Journal of the American College of Cardiology|December 22, 2018
Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID TrialCecilia C Low Wang, Juuso I Blomster, Gretchen Heizer, et al.
Circulation|March 8, 2017
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) AnalysisSamuel M Lindner, Christopher B Fordyce, Anne S Hellkamp, et al.
Circulation. Cardiovascular Quality and Outcomes|May 5, 2021
Establishing Thresholds for Minimal Clinically Important Differences for the Peripheral Artery Disease QuestionnairePoghni A Peri-Okonny, Jingyan Wang, Kensey L Gosch, et al.
American Heart Journal|May 20, 2026
Predictors of ischemic stroke and major bleeding among patients with atrial fibrillation in clinical practicePishoy Gouda, Josephine Harrington, Kelly Arps, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Heart Failure Reviews|January 17, 2026
Rationale and design of MUSIC-HFpEF: a phase 1b, pilot trial evaluating the safety and pharmacodynamic effects of AAV1.SERCA2A in heart failure with preserved ejection fractionMarat Fudim, Satyam Sarma, James P MacNamara, et al.
Circulation. Cardiovascular Interventions|May 17, 2022
One-Year Health Status Outcomes Following Early Invasive and Noninvasive Treatment in Symptomatic Peripheral Artery DiseaseSuveen Angraal, Vittal Hejjaji, Yuanyuan Tang, et al.
Circulation|January 24, 2024
Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial FibrillationSiddharth M Patel, Eugene Braunwald, Jan Steffel, et al.
Heart (British Cardiac Society)|December 3, 2025
Long-term prognostic impact of complete revascularisation defined by CT-derived fractional flow reserveKristian Taekker Madsen, Bjarne Linde Nørgaard, Kristian Altern Øvrehus, et al.
Pageof 60

Showing results (501-510 of 596) with videos related to

Sort By:
Pageof 60
Journal of the American College of Cardiology|December 22, 2018
Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID TrialCecilia C Low Wang, Juuso I Blomster, Gretchen Heizer, et al.
Circulation|March 8, 2017
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) AnalysisSamuel M Lindner, Christopher B Fordyce, Anne S Hellkamp, et al.
Circulation. Cardiovascular Quality and Outcomes|May 5, 2021
Establishing Thresholds for Minimal Clinically Important Differences for the Peripheral Artery Disease QuestionnairePoghni A Peri-Okonny, Jingyan Wang, Kensey L Gosch, et al.
American Heart Journal|May 20, 2026
Predictors of ischemic stroke and major bleeding among patients with atrial fibrillation in clinical practicePishoy Gouda, Josephine Harrington, Kelly Arps, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Heart Failure Reviews|January 17, 2026
Rationale and design of MUSIC-HFpEF: a phase 1b, pilot trial evaluating the safety and pharmacodynamic effects of AAV1.SERCA2A in heart failure with preserved ejection fractionMarat Fudim, Satyam Sarma, James P MacNamara, et al.
Circulation. Cardiovascular Interventions|May 17, 2022
One-Year Health Status Outcomes Following Early Invasive and Noninvasive Treatment in Symptomatic Peripheral Artery DiseaseSuveen Angraal, Vittal Hejjaji, Yuanyuan Tang, et al.
Circulation|January 24, 2024
Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial FibrillationSiddharth M Patel, Eugene Braunwald, Jan Steffel, et al.
Heart (British Cardiac Society)|December 3, 2025
Long-term prognostic impact of complete revascularisation defined by CT-derived fractional flow reserveKristian Taekker Madsen, Bjarne Linde Nørgaard, Kristian Altern Øvrehus, et al.
Pageof 60